Drug Profile
TP 317
Alternative Names: TP-317Latest Information Update: 11 Jan 2024
Price :
$50
*
At a glance
- Originator Thetis Pharmaceuticals
- Class Anti-inflammatories; Small molecules
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Colorectal cancer; Crohn's disease; Pancreatic cancer; Ulcerative colitis
Most Recent Events
- 11 Oct 2023 Pharmacodynamics data from the preclinical studies were presented at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics 2023 (AACR-NCI-EORTC-2023)
- 07 Jun 2023 TP 317 is still in preclinical trials for crohn's disease in USA (PO) (Thetis pharmaceuticals pipeline, June 2023)
- 07 Jun 2023 TP 317 is still in preclinical trials for ulcerative colitis in USA (PO) (Thetis pharmaceuticals pipeline, June 2023)